CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $908 | -19.1% | 20 | 0.0% | 0.00% | – |
| Q2 2023 | $1,123 | -84.0% | 20 | -87.1% | 0.00% | -100.0% |
| Q1 2023 | $7,011 | +11.3% | 155 | 0.0% | 0.00% | +50.0% |
| Q4 2022 | $6,301 | -99.9% | 155 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $10,129,000 | +7.5% | 155 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $9,419,000 | -1.1% | 155 | 0.0% | 0.00% | +33.3% |
| Q1 2022 | $9,525,000 | -96.0% | 155 | -95.0% | 0.00% | -96.2% |
| Q4 2021 | $236,434,000 | -32.3% | 3,120 | 0.0% | 0.08% | -38.9% |
| Q3 2021 | $349,222,000 | -30.9% | 3,120 | 0.0% | 0.13% | -34.2% |
| Q2 2021 | $505,097,000 | +32.9% | 3,120 | 0.0% | 0.20% | +26.8% |
| Q1 2021 | $380,172,000 | +123734.5% | 3,120 | -58.4% | 0.16% | -15.6% |
| Q3 2019 | $307,000 | – | 7,500 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |